001     278928
005     20250606100749.0
024 7 _ |a 10.1016/B978-0-12-822240-9.00009-0
|2 doi
037 _ _ |a DZNE-2025-00654
041 _ _ |a English
100 1 _ |a Berron, David
|0 P:(DE-2719)2812972
|b 0
|e First author
|u dzne
245 _ _ |a Advances in cognitive testing
260 _ _ |c 2025
|b Elsevier
295 1 0 |a Early Detection in Alzheimer' s Disease / Berron, David ; : Elsevier, 2025, ; ISBN: 9780128222409 ; doi:10.1016/B978-0-12-822240-9.00009-0
300 _ _ |a 161 - 184
336 7 _ |a BOOK_CHAPTER
|2 ORCID
336 7 _ |a Book Section
|0 7
|2 EndNote
336 7 _ |a bookPart
|2 DRIVER
336 7 _ |a INBOOK
|2 BibTeX
336 7 _ |a Output Types/Book chapter
|2 DataCite
336 7 _ |a Contribution to a book
|b contb
|m contb
|0 PUB:(DE-HGF)7
|s 1749125649_19817
|2 PUB:(DE-HGF)
520 _ _ |a Recent developments in Alzheimer's disease biomarkers have significantly improved the early detection of Alzheimer's disease pathology (Hansson et al., 2023; Ossenkoppele and Hansson, 2021; Zetterberg and Blennow, 2021) [1-3]. However, while biomarkers for Alzheimer's disease can indicate the underlying brain pathology and have some predictive value for future cognitive decline, they do not provide information about cognitive Alzheimer's disease phenotypes, particularly in early disease stages (Dubois et al., 2021) [4], nor do they represent optimal measures of disease progression. Thus, it is of critical importance to identify, characterize, and monitor cognitive impairment in Alzheimer's disease using cognitive assessments. While capturing subtle cognitive changes and impairment in early disease stages still remains challenging (Weintraub et al., 2018) [5], several new approaches have recently been utilized to improve the early detection of subtle cognitive impairment and decline. In this chapter, I will first provide an overview of novel cognitive test paradigms that are tailored toward cognitive functions of which the functional anatomy overlaps with spatial patterns of accumulation of Alzheimer's disease pathology; these paradigms aim to capture signs of early impairment with greater sensitivity than previous measures. I will then illustrate new approaches to cognitive testing that build on recent technological developments (Koo and Vizer, 2019; Kourtis et al., 2019) [6,7] and aim to assess cognitive performance even outside clinical settings.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef Book
773 _ _ |a 10.1016/B978-0-12-822240-9.00009-0
856 4 _ |u https://pub.dzne.de/record/278928/files/DZNE-2025-00654_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/278928/files/DZNE-2025-00654_Restricted.pdf?subformat=pdfa
|x pdfa
909 C O |o oai:pub.dzne.de:278928
|p VDB
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)2812972
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
920 1 _ |0 I:(DE-2719)5000070
|k AG Berron
|l Clinical Cognitive Neuroscience
|x 0
980 _ _ |a contb
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)5000070
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21